Bereich
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohort
Schmid S, Jochum W, Addeo A, Demmer I, Schär S, Janthur W, Wannesson L, König D, Britschgi C, Frösch P, Bouchaab H, Rothschild S, Blum V, Friedlaender A, Mauti L, Früh M. Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohort. Cancer Immunol Immunother 2020; 69:1605-1613.
19.04.2020Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohort
19.04.2020Cancer Immunol Immunother 2020; 69:1605-1613
Schmid Sabine, Jochum Wolfram, Addeo Alfredo, Demmer Izadora, Schär Sämi, Janthur Wolf-Dieter, Wannesson Luciano, König David, Britschgi Christian, Frösch Patrizia, Bouchaab Hasna, Rothschild Sacha I, Blum Veronika, Friedlaender Alex, Mauti Laetitia A, Früh Martin
Impaired proteolysis by SPPL2a causes CD74 fragment accumulation that can be recognized by anti-CD74 autoantibodies in human ankylosing spondylitis
van Kempen T, Radstake T, Witte T, Baerlecken N, Lebbink R, Driessen C, Nordkamp M, Lindenbergh M, Leijten E, Boes M. Impaired proteolysis by SPPL2a causes CD74 fragment accumulation that can be recognized by anti-CD74 autoantibodies in human ankylosing spondylitis. Eur J Immunol 2020; 50:1209-1219.
14.04.2020Impaired proteolysis by SPPL2a causes CD74 fragment accumulation that can be recognized by anti-CD74 autoantibodies in human ankylosing spondylitis
14.04.2020Eur J Immunol 2020; 50:1209-1219
van Kempen Tessa S, Radstake Timothy R D J, Witte Torsten, Baerlecken Niklas, Lebbink Robert-Jan, Driessen Christoph, Nordkamp Michel Olde, Lindenbergh Marthe F S, Leijten Emmerik F A, Boes Marianne
Genetic heterogeneity highlighted by differential FDG-PET response in diffuse large B-cell lymphoma
Araf S, Fitzgibbon J, Okosun J, Johnson P, Davies A, Rimsza L, Scott D, Graham T, Barrington S, Forrer F, Kumar E, Cogliatti S, Wang J, Bewicke-Copley F, Korfi K, Fehr M. Genetic heterogeneity highlighted by differential FDG-PET response in diffuse large B-cell lymphoma. Haematologica 2020; 105:318-321.
09.04.2020Genetic heterogeneity highlighted by differential FDG-PET response in diffuse large B-cell lymphoma
09.04.2020Haematologica 2020; 105:318-321
Araf Shamzah, Fitzgibbon Jude, Okosun Jessica, Johnson Peter, Davies Andrew, Rimsza Lisa M, Scott David W, Graham Trevor A, Barrington Sally F, Forrer Flavio, Kumar Emil, Cogliatti Sergio B., Wang Jun, Bewicke-Copley Findlay, Korfi Koorosh, Fehr Martin
Radiation dosimetry of 18F-AzaFol: A first inhuman use of a folate receptor PET tracer
Müller J, Früh M, Siano M. Radiation dosimetry of 18F-AzaFol: A first inhuman use of a folate receptor PET tracer. EJNMMI Research 2020; 10
08.04.2020Radiation dosimetry of 18F-AzaFol: A first inhuman use of a folate receptor PET tracer
08.04.2020EJNMMI Research 2020; 10
Müller Joachim, Früh Martin, Siano Marco
Radiation dosimetry of F-AzaFol: A first in-human use of a folate receptor PET tracer
Gnesin S, Prior J, Treyer V, Kaufmann P, Ametamey S, Schibli R, Müller C, Choschzick M, Früh M, Siano M, Meisel A, Burger I, Müller J, Schaefer N. Radiation dosimetry of F-AzaFol: A first in-human use of a folate receptor PET tracer. EJNMMI Res 2020; 10:32.
08.04.2020Radiation dosimetry of F-AzaFol: A first in-human use of a folate receptor PET tracer
08.04.2020EJNMMI Res 2020; 10:32
Gnesin Silvano, Prior John O, Treyer Valerie, Kaufmann Philipp A, Ametamey Simon M, Schibli Roger, Müller Cristina, Choschzick Matthias, Früh Martin, Siano Marco, Meisel Alexander, Burger Irene A, Müller Joachim, Schaefer Niklaus
Impact of Granulocyte Colony-Stimulating Factor (G-CSF) and Epoetin (EPO) on Hematologic Toxicities and Quality of Life in Patients During Adjuvant Chemotherapy in Early Breast Cancer: Results From the Multi-Center Randomized ADEBAR Trial
Bekes I, Janni W, Lato K, Kiechle M, Huober J, Dannecker C, Forstbauer H, Rack B, Harbeck N, Friedl T, Singer S, Eichler M, Fink V. Impact of Granulocyte Colony-Stimulating Factor (G-CSF) and Epoetin (EPO) on Hematologic Toxicities and Quality of Life in Patients During Adjuvant Chemotherapy in Early Breast Cancer: Results From the Multi-Center Randomized ADEBAR Trial. Clin Breast Cancer 2020; 20:439-447.
06.04.2020Impact of Granulocyte Colony-Stimulating Factor (G-CSF) and Epoetin (EPO) on Hematologic Toxicities and Quality of Life in Patients During Adjuvant Chemotherapy in Early Breast Cancer: Results From the Multi-Center Randomized ADEBAR Trial
06.04.2020Clin Breast Cancer 2020; 20:439-447
Bekes Inga, Janni Wolfgang, Lato Krisztian, Kiechle Marion, Huober Jens, Dannecker Christian, Forstbauer Helmut, Rack Brigitte, Harbeck Nadia, Friedl Thomas W P, Singer Susanne, Eichler Martin, Fink Visnja
Epigenetic activation of O-linked β-N-acetylglucosamine transferase overrides the differentiation blockage in acute leukemia
Kampa-Schittenhelm K, Vogel W, Schleicher E, Bonzheim I, Mau-Holzmann U, Illing B, Akmut F, Ganief T, Dreher S, Blumenstock G, Haeusser L, Bühring H, Tsintari V, Bonin M, Haverkamp T, Schittenhelm M. Epigenetic activation of O-linked β-N-acetylglucosamine transferase overrides the differentiation blockage in acute leukemia. EBioMedicine 2020; 54:102678.
06.04.2020Epigenetic activation of O-linked β-N-acetylglucosamine transferase overrides the differentiation blockage in acute leukemia
06.04.2020EBioMedicine 2020; 54:102678
Kampa-Schittenhelm Kerstin, Vogel W, Schleicher E, Bonzheim I, Mau-Holzmann U A, Illing B, Akmut F, Ganief T, Dreher S T, Blumenstock G, Haeusser L, Bühring H J, Tsintari V, Bonin M, Haverkamp T, Schittenhelm Marcus
Integrated Data Analysis of Six Clinical Studies Points Toward Model-Informed Precision Dosing of Tamoxifen
Klopp-Schulze L, Mueller-Schoell A, Neven P, Koolen S, Mathijssen R, Jörger M, Kloft C. Integrated Data Analysis of Six Clinical Studies Points Toward Model-Informed Precision Dosing of Tamoxifen. Front Pharmacol 2020; 11:283.
31.03.2020Integrated Data Analysis of Six Clinical Studies Points Toward Model-Informed Precision Dosing of Tamoxifen
31.03.2020Front Pharmacol 2020; 11:283
Klopp-Schulze Lena, Mueller-Schoell Anna, Neven Patrick, Koolen Stijn L W, Mathijssen Ron H J, Jörger Markus, Kloft Charlotte
Choice of first line systemic treatment in pancreatic cancer among national experts
Glatzer M, Pless M, Pederiva S, Pestalozzi B, Berger M, Inauen R, Winterhalder R, Montemurro M, Horber D, Putora P. Choice of first line systemic treatment in pancreatic cancer among national experts. Pancreatology 2020; 20 (2020):686-690.
31.03.2020Choice of first line systemic treatment in pancreatic cancer among national experts
31.03.2020Pancreatology 2020; 20 (2020):686-690
Glatzer Markus, Pless Miklos, Pederiva S., Pestalozzi Bernhard, Berger M.D., Inauen Roman, Winterhalder Ralf, Montemurro Michael, Horber Daniel, Putora Paul Martin
Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer experts
Früh M, De Ruysscher D, Westeel V, de Marinis F, Paz Ares L, O'Brien M, Felip E, Garrido P, Novello S, Besse B, Cappuzzo F, Califano R, Blackhall F, Reck M, Panje C, Putora P. Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer experts. Lung Cancer 2020; 146:6-11.
30.03.2020Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer experts
30.03.2020Lung Cancer 2020; 146:6-11
Früh Martin, De Ruysscher D, Westeel V, de Marinis F, Paz Ares L, O'Brien M, Felip E, Garrido P, Novello S, Besse B, Cappuzzo F, Califano R, Blackhall F, Reck M, Panje C M, Putora Paul Martin
Do YOU know the Ki-67 index of your breast cancer patients? Knowledge of your institution's Ki-67 index distribution and its robustness is essential for decision-making in early breast cancer
Maranta A, Broder S, Fritzsche C, Knauer M, Thürlimann B, Jochum W, Ruhstaller T. Do YOU know the Ki-67 index of your breast cancer patients? Knowledge of your institution's Ki-67 index distribution and its robustness is essential for decision-making in early breast cancer. Breast 2020; 51:120-126.
23.03.2020Do YOU know the Ki-67 index of your breast cancer patients? Knowledge of your institution's Ki-67 index distribution and its robustness is essential for decision-making in early breast cancer
23.03.2020Breast 2020; 51:120-126
Maranta Angela Fischer, Broder Simon, Fritzsche Constanze, Knauer Michael, Thürlimann Beat, Jochum Wolfram, Ruhstaller Thomas
Population-based SEER analysis of survival in colorectal cancer patients with or without resection of lung and liver metastases
Siebenhüner A, Gueller U, Warschkow R. Population-based SEER analysis of survival in colorectal cancer patients with or without resection of lung and liver metastases. BMC cancer 2020; 20:246.
23.03.2020Population-based SEER analysis of survival in colorectal cancer patients with or without resection of lung and liver metastases
23.03.2020BMC cancer 2020; 20:246
Siebenhüner Alexander R, Gueller Ulrich, Warschkow Rene
Locoregional recurrence risk after neoadjuvant chemotherapy: A pooled analysis of nine prospective neoadjuvant breast cancer trials
Werutsky G, Nekljudova V, Vladimirova V, Kühn T, Rhiem K, Huober J, Krug D, Link T, Schneeweiss A, Gerber B, Jackisch C, Tesch H, Denkert C, Seiler S, Blohmer J, Fasching P, Hanusch C, Untch M, Loibl S. Locoregional recurrence risk after neoadjuvant chemotherapy: A pooled analysis of nine prospective neoadjuvant breast cancer trials. Eur J Cancer 2020; 130:92-101.
13.03.2020Locoregional recurrence risk after neoadjuvant chemotherapy: A pooled analysis of nine prospective neoadjuvant breast cancer trials
13.03.2020Eur J Cancer 2020; 130:92-101
Werutsky Gustavo, Nekljudova Valentina, Vladimirova Valentina, Kühn Thorsten, Rhiem Kerstin, Huober Jens, Krug David, Link Theresa, Schneeweiss Andreas, Gerber Bernd, Jackisch Christian, Tesch Hans, Denkert Carsten, Seiler Sabine, Blohmer Jens-Uwe, Fasching Peter A, Hanusch Claus, Untch Michael, Loibl Sibylle
Update Breast Cancer 2020 Part 1 - Early Breast Cancer: Consolidation of Knowledge About Known Therapies
Schneeweiss A, Luftner D, Fehm T, Tesch H, Overkamp F, Welslau M, Pöschke P, Kolberg H, Fasching P, Thill M, Huober J, Belleville E, Ettl J, Janni W, Lux M, Wöckel A, Müller V, Hartkopf A, Schütz F. Update Breast Cancer 2020 Part 1 - Early Breast Cancer: Consolidation of Knowledge About Known Therapies. Geburtshilfe Frauenheilkd 2020; 80:277-287.
04.03.2020Update Breast Cancer 2020 Part 1 - Early Breast Cancer: Consolidation of Knowledge About Known Therapies
04.03.2020Geburtshilfe Frauenheilkd 2020; 80:277-287
Schneeweiss Andreas, Luftner Diana, Fehm Tanja N, Tesch Hans, Overkamp Friedrich, Welslau Manfred, Pöschke Patrik, Kolberg Hans-Christian, Fasching Peter A, Thill Marc, Huober Jens, Belleville Erik, Ettl Johannes, Janni Wolfgang, Lux Michael P, Wöckel Achim, Müller Volkmar, Hartkopf Andreas D, Schütz Florian
IL-36γ drives skin toxicity induced by EGFR/MEK inhibition and commensal Cutibacterium acnes.
Satoh T, Mellett M, Meier-Schiesser B, Fenini G, Otsuka A, Beer H, Rordorf T, Maul J, Hafner J, Navarini A, Contassot E, French L. IL-36γ drives skin toxicity induced by EGFR/MEK inhibition and commensal Cutibacterium acnes. J Clin Invest 2020; 130:1417-1430.
02.03.2020IL-36γ drives skin toxicity induced by EGFR/MEK inhibition and commensal Cutibacterium acnes.
02.03.2020J Clin Invest 2020; 130:1417-1430
Satoh Takashi K, Mellett Mark, Meier-Schiesser Barbara, Fenini Gabriele, Otsuka Atsushi, Beer Hans-Dietmar, Rordorf Tamara, Maul Julia-Tatjana, Hafner Jürg, Navarini Alexander A, Contassot Emmanuel, French Lars E
Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project
Fox C, Hitz F, Montoto S, Nagler A, Martinez V, De Souza C, Fernandez-Alvarez R, Ballova V, Gabús R, Inghirami G, Federico M, Spina M, Dlouhy I, Civallero M, Ko Y, Manni M, Skrypets T, Pileri S, Kim S, Cabrera M, Shustov A, Chiattone C, Horwitz S, Kim W. Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project. Lancet Haematol 2020; 7:e284-e294.
24.02.2020Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project
24.02.2020Lancet Haematol 2020; 7:e284-e294
Fox Christopher P, Hitz Felicitas, Montoto Silvia, Nagler Arnon, Martinez Virginia, De Souza Carmino A, Fernandez-Alvarez Ruben, Ballova Veronika, Gabús Raul, Inghirami Giorgio, Federico Massimo, Spina Michele, Dlouhy Ivan, Civallero Monica, Ko Young-Hyeh, Manni Martina, Skrypets Tetiana, Pileri Stefano, Kim Seok Jin, Cabrera Maria Elena, Shustov Andrei R, Chiattone Carlos S, Horwitz Steven M, Kim Won Seog
Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy
Di Cosimo S, Pusztai L, Pritchard K, Nuciforo P, Vincent-Salomon A, Symmans F, Apolone G, de Braud F, Iorio M, Verderio P, Untch M, de Azambuja E, Appierto V, Pizzamiglio S, Silvestri M, Baselga J, Piccart M, Huober J, Izquierdo M, de la Pena L, Hilbers F, Daidone M. Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy. Int J Mol Sci 2020; 21
18.02.2020Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy
18.02.2020Int J Mol Sci 2020; 21
Di Cosimo Serena, Pusztai Lajos, Pritchard Kathleen, Nuciforo Paolo, Vincent-Salomon Anne, Symmans Fraser, Apolone Giovanni, de Braud Filippo G, Iorio Marilena V, Verderio Paolo, Untch Michael, de Azambuja Evandro, Appierto Valentina, Pizzamiglio Sara, Silvestri Marco, Baselga José, Piccart Martine, Huober Jens, Izquierdo Miguel, de la Pena Lorena, Hilbers Florentine S, Daidone Maria Grazia
Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: results of a randomized study - SAKK 22/99
Eppenberger-Castori S, Klingbiel D, Ruhstaller T, Dietrich D, Rufle D, Rothgiesser K, Pagani O, Thürlimann B. Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: results of a randomized study - SAKK 22/99. BMC cancer 2020; 20:114.
11.02.2020Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: results of a randomized study - SAKK 22/99
11.02.2020BMC cancer 2020; 20:114
Eppenberger-Castori Serenella, Klingbiel Dirk, Ruhstaller Thomas, Dietrich Daniel, Rufle Daniel Alexander, Rothgiesser Karin, Pagani Olivia, Thürlimann Beat
Targeting MET in EGFR resistance in non-small-cell lung cancer-ready for daily practice?
Schmid S, Früh M, Peters S. Targeting MET in EGFR resistance in non-small-cell lung cancer-ready for daily practice?. Lancet Oncol 2020; 21:320-322.
03.02.2020Targeting MET in EGFR resistance in non-small-cell lung cancer-ready for daily practice?
03.02.2020Lancet Oncol 2020; 21:320-322
Schmid Sabine, Früh Martin, Peters Solange
Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992-2003
STAMPEDE Investigators, Parikh O, O'Sullivan J, Omlin A, Nikapota A, Lydon A, Gibbs S, Gale J, Capaldi L, Birtle A, Beesley S, Protheroe A, Rudman S, Srihari N, James N, Parmar M, Sydes M, Zarkar A, Wylie J, Wallace J, Wagstaff J, Tolan S, Tanguay J, Simms M, Brown J, Russell J, Rush H, Cross W, Cook A, Chowdhury S, Calvert J, Brawley C, Attard G, Amos C, Hoyle A, Ingleby F, Ali A, Dearnaley D, Douis H, Gilbert D, Ritchie A, Parker C, Millman R, Matheson D, Mason M, Malik Z, MacNair A, Langley R, Jones R, Gillessen S, Clarke N. Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992-2003. Ann Oncol 2020; 31:442.
31.01.2020Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992-2003
31.01.2020Ann Oncol 2020; 31:442
STAMPEDE Investigators, Parikh O, O'Sullivan J M, Omlin Aurelius, Nikapota A, Lydon A, Gibbs S, Gale J, Capaldi L, Birtle A, Beesley S, Protheroe A, Rudman S, Srihari N N, James N D, Parmar M K B, Sydes M R, Zarkar A, Wylie J, Wallace J, Wagstaff J, Tolan S, Tanguay J S, Simms M, Brown J, Russell J M, Rush H, Cross W, Cook A, Chowdhury S, Calvert J, Brawley C D, Attard G, Amos C L, Hoyle A, Ingleby F C, Ali A, Dearnaley D P, Douis H, Gilbert D, Ritchie A W S, Parker C C, Millman R, Matheson D, Mason M D, Malik Z, MacNair A, Langley R E, Jones R J, Gillessen S, Clarke N W